Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

Core Viewpoint - Aurora Cannabis Inc. has received two licenses from Germany's Federal Institute for Drugs and Medical Devices, allowing for continued domestic cultivation and the trial of additional cultivars, positioning the company to expand its offerings in the growing German medical cannabis market [1][2][3] Group 1: Licenses and Expansion - The new licenses enable Aurora to continue domestic cultivation and to cultivate an additional approved product, enhancing its offerings to the German patient base [1][2] - Aurora plans to trial up to seven additional novel cultivars at its EU GMP facility in Leuna, Germany, under the dedicated R&D license [1][2] Group 2: Commitment and Quality - The company emphasizes its commitment to quality and compliance, which has led to the granting of additional licenses, reflecting its established leadership in the region [2][3] - Since 2021, Aurora has been cultivating approximately 1,000 kg (about 2204 lb) of medical cannabis flower annually as part of a tender agreement with BfArM [2] Group 3: Industry Impact - Aurora supports Germany's regulatory reforms, anticipating broader acceptance of medical cannabis and modern frameworks across Europe [3] - The company's expertise in developing high-quality and innovative products positions it as a leader to meet growing patient demand [3]